GOT1 and pancreatic neoplasm: In pancreatic cancer, Yoshida and colleagues tested an inhibitory compound (PF-04859989) that covalently bonded to cCAT, promoting inhibitory effects in a time- and PLP-dependent fashion, further showing selective anti-proliferative effects towards pancreas cancer cell lines [163].